FibroBiologics, Inc. Capital Expenditures
FibroBiologics, Inc. (FBLG) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-07-31
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $6.00K, a 45.45% decline year-over-year.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $262.00K, a 42.39% increase from fiscal 2024.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $184.00K, a 62.83% decline from fiscal 2023.
- FibroBiologics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $495.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $0.00 10-Q · filed 2026-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-07-31 | $6.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $6.00K derived: sum of 3 quarters · filed 2026-04-30 | $219.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.00K derived: sum of 2 quarters · filed 2026-02-24 | $219.00K derived: sum of 3 quarters · filed 2026-07-31 | $262.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $219.00K derived: sum of 2 quarters · filed 2026-07-31 | $262.00K 10-Q · filed 2025-10-31 | $361.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $256.00K 10-Q · filed 2026-07-31 | $355.00K derived: sum of 3 quarters · filed 2026-07-31 | $366.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $43.00K 10-Q · filed 2026-04-30 | $142.00K derived: sum of 2 quarters · filed 2026-04-30 | $153.00K derived: sum of 3 quarters · filed 2026-04-30 | $219.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $110.00K derived: sum of 2 quarters · filed 2026-02-24 | $176.00K derived: sum of 3 quarters · filed 2026-02-24 | $184.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $77.00K derived: sum of 2 quarters · filed 2025-10-31 | $85.00K 10-Q · filed 2025-10-31 | $87.00K derived: sum of 4 quarters · filed 2025-10-31 |
| 2024-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $74.00K 10-Q · filed 2025-07-31 | $76.00K derived: sum of 3 quarters · filed 2025-07-31 | $489.00K derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $8.00K 10-Q · filed 2025-05-14 | $10.00K derived: sum of 2 quarters · filed 2025-05-14 | $423.00K derived: sum of 3 quarters · filed 2025-05-14 | $447.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $415.00K derived: sum of 2 quarters · filed 2025-03-31 | $439.00K derived: sum of 3 quarters · filed 2025-03-31 | $495.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $437.00K derived: sum of 2 quarters · filed 2024-11-12 | $493.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $80.00K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $56.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |